Prevention & care

Systemic sclerosis: localized versus systemic scleroderma, skin patterns, vascular disease, lung outcomes, and care

6 sources · Latest source check 2026-10-09 UTC

On this page

Systemic sclerosis is an autoimmune disease involving blood vessels, immune activity and excess connective-tissue scarring, or fibrosis. Skin can thicken and tighten, but internal organs may also be affected. “Scleroderma” is a broader term: localized scleroderma and systemic sclerosis have different patterns and should not be collapsed into one diagnosis.[1]

Similar names describe different distributions

Similar names describe different distributions
Term	What the label concerns
Localized scleroderma / morphea	Skin and sometimes underlying tissues, including muscle or bone.[4]
Limited cutaneous systemic sclerosis	More restricted skin distribution; internal disease can still occur.[4]
Diffuse systemic sclerosis	More extensive skin involvement and a different pattern of organ risks.[4]
Fibrosis	Excess scarring and tissue thickening associated with collagen.[1]

Limited skin involvement does not mean that all disease is limited to skin

The NHS describes lung and digestive involvement in limited cutaneous systemic sclerosis. “Limited” therefore refers to the skin pattern, rather than a guarantee of harmless disease or absent organ involvement. Localized morphea is a separate category; even there, effects on underlying tissues can matter. The clinical scope needs to be established before borrowing information from another subtype.[4]

Collagen is normal; its excessive deposition is part of the disease process

NIAMS describes immune abnormalities, altered blood vessels and overproduction of collagen by connective-tissue cells. Collagen itself is a normal structural material. Naming it as part of fibrosis does not identify one proven cause of the disease or establish that a food, supplement or “collagen detox” will reverse it.[1]

Raynaud symptoms concern circulation

The ACR describes finger or toe color changes, pain, numbness and sometimes ulcers, often triggered by cold. These vascular features are different from skin thickness. Keeping the body and extremities warm and protecting vulnerable skin are supportive measures; they do not settle which systemic treatments or organ investigations are needed.[3]

Diagnosis combines findings; an antibody result alone is insufficient

NIAMS describes history, examination and selected antibody or tissue tests. Antibodies can also arise for other reasons, so blood tests alone do not establish the diagnosis. CT, echocardiography and lung-function tests investigate different organ questions rather than being interchangeable tests for the whole disease.[2]

Lung scarring and pulmonary hypertension are different complications

NIAMS distinguishes pulmonary fibrosis, involving lung-tissue scarring, from pulmonary hypertension, involving increased pressure in the lung circulation. They require different assessments and treatment approaches. Breathlessness can have more than one explanation, so an assumed “lung problem” is not a sufficient subtype diagnosis. Monitoring may detect important disease before symptoms clearly identify it.[2]

Treatment follows the manifestation

The ACR discusses medicines affecting circulation, reflux, immune activity and lung fibrosis. A treatment aimed at widening blood vessels does not automatically treat lung scarring; a medicine used for interstitial lung disease does not establish effectiveness for pulmonary arterial hypertension. The same patient may need several specialties and different outcome measures.[3]

The 2024 BSR guideline emphasizes organ assessment and risk patterns

The British Society for Rheumatology guideline updates its 2015 predecessor. It includes cardiopulmonary, kidney and gastrointestinal complications and the wider effect of disease. Skin and antibody patterns help inform risk assessment, and nailfold capillary assessment is part of its initial-evaluation recommendations. These findings contribute context rather than replacing the clinical diagnosis.[5]

It primarily addresses systemic sclerosis, with consideration of younger people; localized morphea and several scleroderma-like conditions are outside its stated scope. The recommendations combine published evidence and expert judgment. Here, the original executive abstract and selected introductory recommendations were inspected, not every evidence table. Counting its main text and executive summary as two independent bodies of evidence would be misleading.[5]

Renal crisis is an urgent complication

NIAMS describes scleroderma renal crisis as uncommon but serious, involving rapid kidney deterioration and often a dangerous blood-pressure rise. It advises prompt contact for unusual blood pressure or new symptoms. Certain medicines, including corticosteroids, can increase concern. This educational explanation does not select treatment or make a new severe presentation suitable for routine home observation.[2]

Supportive care addresses practical consequences

The NHS describes physiotherapy for movement and occupational therapy for adjustments at home or work. Difficulty using the hands can affect tasks far beyond a skin score. An improvement in a laboratory or lung outcome and an improvement in daily independence are different achievements; both deserve attention in a care discussion.[4]

Digestive symptoms and emotional burden also matter

The ACR discusses meal adjustments for reflux, physical therapy and support for mood or coping. These measures address comfort and participation alongside medical care. They should not be presented as proof that systemic fibrosis has been cured or as a substitute for organ monitoring.[3]

Evidence & uncertainty

There is no single treatment that reverses every manifestation. A lung trial found a slower average decline in one lung-function measurement with nintedanib, without demonstrated benefit on its skin or respiratory-quality-of-life secondary outcomes. Organ-specific benefits, treatment harms and uncertainty need explanation before a medicine is described simply as a “scleroderma treatment.”[6]

Selected-source overview · Independent review pending

Published questions

Is localized morphea the same disease pattern as systemic sclerosis?

Selected-source overview · Independent review pending. Read the evidence context.

Localized and systemic scleroderma are distinct categories.[4]

Evidence behind this answer

Scleroderma
agency condition or prevention explanation · 2023
Selected relevant original official page passages inspected · March 2023: morphea, limited/diffuse patterns and functional support